GLP-1 single agonist vs. GLP-1/GIP dual agonist: Why does telopoietin have greater weight loss potential?
Currently, GLP-1 receptor agonists have become the mainstream drugs in the field of weight loss and diabetes treatment , among which single agonists (such as semaglutide, trade name: Vigovi) and dual agonists (such as telpotide) are the two most popular types of drugs.
GLP-1 single agonists control body weight mainly by reducing appetite and delaying gastric emptying , while GLP-1/GIP dual agonists add the ability to promote fat metabolism , making the weight loss effect stronger and long-term weight management more stable.
So, why can the dual-agonist telocycline bring stronger weight loss effects? This article will analyze in detail the mechanism of action, clinical research data, side effects and long-term weight maintenance ability .
1. GLP-1 vs. GLP-1/GIP : Comparison of Mechanisms of Action
|
Mechanism of action |
GLP-1 monoagonist (semaglutide) |
GLP-1/GIP dual agonist (Telportide) |
|
Reduces appetite |
powerful |
powerful |
|
Delays gastric emptying |
powerful |
powerful |
|
Promote fat metabolism |
No direct effect |
Strong ( GIP effect) |
|
Improved insulin sensitivity |
Moderate |
Stronger ( GIP effect) |
|
Reduce gastrointestinal side effects |
none |
Stronger ( GIP can reduce nausea and other discomfort) |
📌 Core differences :
- GLP-1 monoagonists (such as semaglutide) mainly act on the appetite center of the brain , reducing food intake while delaying gastric emptying , making it easier for people to reduce calorie intake.
- GLP-1/GIP dual agonists (such as tilportide) promote lipolysis and increase insulin sensitivity through GIP based on the action of GLP-1 , resulting in greater weight loss and more comprehensive metabolic improvements .
- The GIP effect of tipol can also reduce GLP-1 -related nausea and improve long-term tolerability .
in conclusion :
• GLP-1 single agonists mainly rely on reducing appetite and delaying gastric emptying, while GLP-1/GIP dual agonists additionally enhance fat metabolism capacity, so tepoxetine has a stronger weight loss effect.
2. Comparison of clinical research data: Which one is better for weight loss?
|
Research |
GLP-1 monoagonist (semaglutide) |
GLP-1/GIP dual agonist (Telportide) |
|
STEP-1 study (semaglutide) |
16.9% weight loss after 68 weeks |
- |
|
SURMOUNT-1 study (tepoxetine) |
- |
22.5% weight loss after 72 weeks |
|
Proportion of patients with weight loss ≥20% |
36% |
57% |
📌 Data analysis :
• In the STEP-1 study (semaglutide), patients taking the highest dose achieved a 16.9% weight loss , with 36% of subjects losing more than 20% of their body weight .
• In the SURMOUNT-1 study (tebuconazole), patients taking the highest dose achieved a 22.5% weight loss , with 57% of participants losing more than 20% of their body weight .
• The weight loss effect of tebuconazole was 5.6% higher than that of semaglutide , and a higher proportion of patients achieved a weight loss target of more than 20% .
📌 Why is tepoxetine more effective in weight loss?
• GLP-1 reduces appetite + GIP accelerates fat metabolism . The dual mechanism allows the body to burn fat more efficiently rather than just reducing calorie intake.
• GIP can also improve insulin sensitivity, reduce insulin resistance, and further optimize metabolism .
in conclusion :
• If the goal is to maximize weight loss, a GLP-1/GIP dual agonist (tepoltide) is more effective than a single agonist (semaglutide).
3. Side effect comparison: Which one is better tolerated?
|
Side effect category |
GLP-1 monoagonist (semaglutide) |
GLP-1/GIP dual agonist (Telportide) |
|
Nausea and vomiting |
Higher ( 44% experienced nausea, 24% experienced vomiting) |
Lower ( 31% experienced nausea, 18% experienced vomiting) |
|
Diarrhea / constipation |
May occur |
Possible, but mild |
|
Hypoglycemia (non-diabetic people) |
Low |
Low |
|
Weight rebound after stopping medication |
Faster |
Slow |
📌 Side effect analysis :
• The main side effect of GLP-1 drugs is gastrointestinal discomfort (such as nausea, vomiting, and diarrhea), but the GIP effect of tepoxetine can reduce these side effects and therefore is better tolerated .
• GLP-1 monoagonists (such as semaglutide) rebound faster after discontinuation, while telpotide has a more stable weight maintenance effect .
in conclusion :
• If you have been unable to adhere to semaglutide because of side effects (such as nausea and vomiting), telpotide may be a better choice.
4. Conclusion: Why does tepoxetine have a greater potential for weight loss?
- The mechanism of GLP-1/GIP dual agonists is stronger :
• GLP-1 effect : Reduce appetite and delay gastric emptying.
• GIP function : accelerate fat burning, improve insulin sensitivity, and reduce gastrointestinal discomfort.
- Clinical research data show that tebuconazole has a stronger weight loss effect :
• After 72 weeks, the average weight loss was 22.5% , which was higher than that with semaglutide ( 16.9% ).
• More than 57% of patients lost more than 20% of their body weight , compared with only 36% with semaglutide.
- Fewer side effects and better tolerance :
• GIP can reduce nausea and vomiting and improve long-term compliance .
• Weight is maintained more stably and the risk of rebound after stopping the medication is lower .
📌 Final Recommendations : ✔ If you are looking to achieve maximum weight loss, telopoietin is a better choice. ✔ If you have difficulty tolerating the side effects of semaglutide, telpotide may be a milder alternative.
--------------------------------
Welcome to add customer service to get new customer discount
Customer Service 1 ： AobMedical
Customer Service 2 ： Aob202404
Kent : +1 6462071346
Asakusa makeup: +81 8070566715
